

1 Early intervention with a glycerol throat spray containing cold-adapted cod trypsin after self-
2 diagnosis of the common cold: a randomised prospective, parallel group and single-blind
3 methods trial

4 (Glycerol-cod trypsin spray in common cold)

5 B. Fredrik Lindberg, Ida Nelson, Jonas Ranstam, Donald K. Riker

6

7 Enzymatica AB, 223 70 Lund, Sweden (B. Fredrik Lindberg, MD, PhD, Ida Nelson,
8 MScBA). Mdas AB, 271 54 Ystad, Sweden (Jonas Ranstam, PhD), On Point Advisors, LLC,
9 Scottsdale, AZ 85250, USA (Donald K. Riker, PhD.)

10

11 **Abstract**

12 Background: A glycerol throat spray containing cold-adapted cod trypsin (GCTS) deactivates
13 common cold virus *in vitro* and decreases pharyngeal rhinovirus load after inoculation in
14 humans. We relied on early self-diagnosis and evaluated two different scales to detect a
15 treatment effect in naturally occurring common colds.

16 Methods: Adults were enrolled in this randomised, prospective, parallel group, single-blind
17 study to begin treatment six times daily at first sign of a common cold or were assigned to a
18 non-treated group. Jackson's symptom scale and the 9-item Wisconsin Upper Respiratory
19 Symptom Survey (WURSS)-21 quality of life (QoL) domain were recorded daily by subjects
20 and area under the curve over 12 days (AUC_{1-12}) calculated.

21 Results: Treatment resulted in reduced symptoms with an AUC_{1-12} of 45.1 ± 32.5 for Jackson
22 scores compared to 53.8 ± 35.7 in the controls ($p=0.023$). AUC_{1-12} for the 9-item WURSS-21

23 QoL domain was likewise improved, 113.6 ± 107.7 and 152.7 ± 126.3 ($p=0.006$),
24 respectively. During the first four days fewer of the treated subjects (35.3%) used rescue
25 medication than did the control group (50.4%, $p=0.014$).

26 Conclusions: Reduction in common cold symptoms was seen with treatment with a glycerol
27 throat spray containing cold-adapted cod trypsin. This effect was best detected with the 9-item
28 WURSS-21 QoL domain.

29 Keywords: glycerol, (cod) trypsin, common cold, quality of life, oral spray

30

31

32

33

34 **BACKGROUND**

35 The common cold is a self-limiting respiratory viral infection not only affecting the
36 individual, but also the society in its high costs and lost productivity [1, 2]. The cause of the
37 common cold is infection by one of over 200 known respiratory viruses, typically
38 rhinoviruses, or coronaviruses, influenza viruses, adenoviruses, parainfluenza viruses,
39 respiratory syncytial viruses and enteroviruses [3]. Rhinovirus is well adapted to its host
40 initially overcoming innate epithelial barriers, interferon release and adaptive immune
41 responses. The diversity of respiratory viral pathogens has so far foiled any attempt to find a
42 universal cure [4-6]. After inoculation virus is transported from the nose back to the
43 nasopharynx where infection of the mucosa is first established [7]. Local symptom
44 development starts with sore scratchy throat and malaise quickly followed by nasal
45 congestion, rhinorrhoea, sneezing and finally cough [8].

46 In an attempt to halt local virus propagation during the incubation period and thereby
47 alleviating and shortening the common cold, a technology has been developed consisting of a
48 hyperosmotic glycerol solution containing cold-adapted trypsin from the Atlantic cod (*Gadus*
49 *morhua*) (GCTS) [9]. When sprayed onto the throat the solution forms a transient barrier
50 across the oro-pharynx that acts osmotically while at the same time deactivating proteins
51 viruses use to bind and enter the host cell. The spray solution has demonstrated broad antiviral
52 activity *in vitro* deactivating 64-100% of virus activity [10, 11]. In a double-blind pilot study
53 of healthy volunteers inoculated intranasally with rhinovirus-16 the barrier solution reduced
54 pharyngeal virus load significantly compared to placebo and reduced the disease progression
55 assessed by the Jackson scale [12].

56 In order to intervene at the very first sign of a common cold we conducted a prospective,
57 single-blind, randomised and comparative multicentre methodology study to investigate a

58 clinical design that relies on self-diagnosis to start treatment at the first perceived signals of
59 common cold presence. We believed that early and sustained intervention during the
60 prodromal phase would reduce viral infectivity, replication and local spread resulting in a
61 reduced symptom burden, improved quality of life and possibly fewer days of colds illness.
62 The primary objective of this study was to investigate the ability of two different rating scales
63 to detect these meaningful benefits of early intervention in the common cold with GCTS.

64

65 **METHODS**

66 **Study design and population**

67 This was a prospective, multicentre, randomised, single-blind (investigator) study using a
68 parallel-group design that compares early intervention with the investigational device (GCTS)
69 to no treatment in patients with naturally occurring common colds. After local Ethics
70 Committee approval at Charité Hospital (Berlin, Germany), and written informed consent,
71 subjects were recruited to six centres located in the Berlin area through advertising. Women
72 of child-bearing potential with a negative pregnancy test and agreeing to use appropriate
73 contraception methods were eligible for inclusion. Men and women (18-70 years) with at least
74 three occurrences of common cold within the last 12 months, but generally in good health
75 and ready to comply with trial procedures were eligible and screened for entry against
76 inclusion and exclusion criteria. Exclusion criteria consisted of known allergy or
77 hypersensitivity to the components of the investigational product, history and/or presence of a
78 clinically significant condition/disorder which per investigator's judgement could interfere
79 with the results of the study, or the safety of the subject, influenza vaccination within the last
80 3 months prior to V1 and during the study, regular use of products that could influence the

81 study outcome, pregnant or nursing women, history of or current abuse of drugs, alcohol or
82 medication, participation in the present study of a person living in the same household as the
83 subject, inability to comply with study requirements according to investigator's judgement
84 and participation in another clinical study within 30 days of V1 or during the study.

85 There were no changes to the study design during the conduct of the study. In addition to the
86 analyses defined in the statistical analysis plan (SAP) post hoc analyses were performed as
87 defined in the addendum to the SAP.

88 The trial was registered at ClincialTrials.gov, number NCT03831763, and was performed in
89 compliance with the principles of the World Medical Association (Declaration of Helsinki),
90 ICH GCP E6, German Act on Medical Devices (MPG) §23b and ISO 14155.

91 **Randomisation and masking**

92 The subjects, the study site staff handling the investigational product, and the study monitors
93 were aware of the allocated arms. All others involved in the study, including investigators
94 performing the clinical assessments of common cold, statisticians and the sponsor were
95 blinded to the allocation. The subjects were randomised (1:1) at the screening visit to the
96 treatment or control group. Randomisation numbers were assigned to the subjects in a
97 sequential order upon enrolment by the investigator, based on time of randomisation at each
98 investigational site. Several whole blocks of four were allocated to each site. The
99 randomisation list was concealed and stored under lock and key by the sponsor until after
100 database closure and sign-off of the statistical analysis plan at which time it was provided to
101 the external statistician responsible for the statistical analysis.

102

103

104 **Procedures**

105 At the screening and enrolment visit eligible subjects once randomised (1:1) to one of two
106 groups received the subject diary to be used throughout the study. Those randomised to the
107 treatment group received the investigational product, a throat spray consisting of glycerol,
108 water, trypsin secreted from the pyloric caeca of the Atlantic cod (*Gadus morhua*), ethanol
109 (<1 %), calcium chloride, trometamol (Tris buffer) and menthol (ColdZyme[®] Mouth Spray,
110 Enzymatica, Sweden) to be sprayed twice (1 dose = 340 µl) every second hour up to 6 times
111 daily. The subjects were blinded to the commercial name as the investigational products were
112 relabelled for investigational use only. All participants were instructed to start the diary
113 ratings at the start of a cold when answering "Yes" to the binary question "Do you think you
114 might be having the first signs of a common cold?" and simultaneously experiencing a total
115 Jackson score of at least 1 (mild = present, but not disturbing or irritating) for any symptom
116 except headache. Subjects in the treatment arm of the study were instructed to start treatment
117 at that time. It is unlikely that the allocation process at the initial enrolment visit during which
118 subjects were entered into the colds surveillance period would introduce investigator bias
119 affecting randomly occurring colds at a later time in either group.

120 From the first day of entering the treatment phase the subjects started to record their
121 symptoms twice daily once in the morning and once in the evening using the Jackson scale
122 [13] and once daily in the evening using the 9-item Wisconsin Upper Respiratory Symptom
123 Survey (WURSS-21) Quality of Life (QoL) domain [14]. All subjects answered a daily binary
124 question in the evening "Do you think that you are still having a common cold?". They also
125 recorded the use of the investigational product (treatment group only) and any use of rescue
126 medication, including paracetamol (acetaminophen), maximum 2 g/day, ibuprofen,
127 maximum 400 mg/day or saline nose drops or spray, if needed for symptom relief.

128 The Jackson score was calculated by summing the scores for the following 8 symptoms: sore
129 throat, blocked nose, runny nose, cough and sneezing (local symptoms) as well as headache,
130 malaise, and chilliness (systemic symptoms). Symptoms were assessed on a 4-point scale:
131 0 = none, 1 = mild, 2 = moderate, 3 = severe. The 9 item (items 12 to 20) quality of
132 life (QoL) domain of the WURSS-21 was calculated by summing the individual scores
133 recorded for the question “How much has your cold interfered with your ability to...: Think
134 clearly, sleep well, breathe easily, walk-climb stairs-exercise, accomplish daily activities,
135 work outside the home, work inside the home, interact with others, and live your personal
136 life”. Response options ranged from 0 = “Not at all” to 7 = “Severely”. A lower value
137 corresponds to an improved quality of life.

138 Within 3 days of experiencing the first perceptions of a common cold and having had
139 recorded subjective symptoms the subjects presented to the investigator for a physical
140 examination and confirmation of common cold signs. The investigator on site was blinded as
141 to a subject’s allocation. The third and last visit to the study site had to take place by day 16
142 (+/-4 days) after the start of a cold. Subjects with no symptoms during the study period
143 attended a termination visit 16 weeks (+/-7 days) after enrolment. These terminal visits would
144 not influence subjective data already collected.

145 **Outcomes**

146 Primary outcomes were individual daily ratings using the Jackson scale and the 9-item QoL
147 domain subscore taken from the Wisconsin Upper Respiratory Symptom Survey WURSS-21.
148 Using these data area under the curve was calculated over the 12 days from the start of a cold
149 (AUC_{1-12}). AUC is a measure of the total symptom burden suffered during a common cold.
150 Other outcomes included: investigator confirmation of participants’ self-diagnosis through
151 objective signs within 3 days after symptom start, use of concomitant symptom relieving

152 rescue medication, adverse events, device deficiencies, duration of common cold, and global
153 evaluation of efficacy. Measures of duration of a cold do not reflect the severity, symptom
154 burden or bothersomeness of the illness, only a return to absolute wellness. Primary data in
155 case record forms and subject diaries were used to assess endpoints.

156 **Statistical Analyses**

157 The number of subjects enrolled was determined on the basis of a previous pilot study [12]
158 and the inter- and intra-individual variability collected from other published studies [15, 16].
159 The enrolment was extended from the planned 300 subjects to include a total of 400 subjects
160 during the course of the study, to ensure entry of a minimum of 200 subjects experiencing
161 common cold symptoms.

162 The full analysis set (FAS) consists of all randomised subjects meeting the inclusion/
163 exclusion criteria (n=400) and for whom there is at least one observation after the onset of
164 common cold symptoms. Subjects in the treatment group must have received at least one dose
165 of the investigational product (n=273) excluding those who at a later stage were detected to
166 have violated the exclusion/inclusion criteria (n=267, treated=136 and control group=131).
167 Safety analyses included all randomly assigned participants. The definition of the FAS
168 population took place prior to unblinding and statistical analysis.

169 All group comparisons are exploratory. Unless otherwise stated the evaluation of endpoints is
170 based on the FAS. Individual areas under the curve (AUC) for Jackson scores and the 9-item
171 WURSS-21 QoL domain were assessed by applying the trapezoidal approximation over 12
172 days and presented as means and SD. Hypothesis-generating statistical tests comparing the
173 two groups were performed using the Mann-Whitney-U test. The Wilcoxon's signed ranks
174 test was used for pre/post comparisons within the treatment groups, and the χ^2 -squared test is

175 used for comparing frequencies between the two treatment groups. Individual items of the
176 WURSS-21 and Jackson scores were compared between the treatment groups using normal
177 deviate tests (z-tests) of the mean AUCs. The results are presented in a forest plot produced
178 by the package forest plot with R version 3.5.2. The statistical calculations were performed
179 using SPSS Statistics version 22.0.

180 **RESULTS**

181 Between Jan 25, 2018, and April 20, 2018, 400 eligible subjects were recruited and randomly
182 assigned to treatment group (n=200) or control group (n=200). The last patient was completed
183 on June 5, 2018. After perceiving the start of a common cold, subjects entered the treatment
184 phase (n=273, Figure 1). Prior to unblinding protocol deviations were identified and classified
185 resulting in six exclusions from the FAS (three from each group). Baseline characteristics are
186 described in Table 1.

187

188 The common cold started with an almost identical burden of symptoms in the two groups with
189 a Jackson score of 7.59 ± 4.68 in the treatment group and 7.46 ± 5.34 in the control group
190 ($p=0.654$) on the first morning. The signs of a common cold was confirmed clinically by the
191 blinded investigator within three days from the start of a perceived common cold for all
192 subjects in the control group (131 of 131), and for 133 of 136 (97.8 %) in the treatment group.
193 On the morning of the third day a significantly lower Jackson score was seen in the treatment
194 group (8.29 ± 5.07) compared to the control group (9.59 ± 5.31 ; $p=0.035$). This significant
195 difference was maintained during day 4 and 5 becoming less evident on the morning of day 6
196 ($p=0.056$). The total Jackson score diminished below 1.0 on the morning of day 10 in the
197 treatment group compared to the morning of day 12 in the control group.

198 The total Jackson score intensity over 12 days showed an AUC_{1-12} of 45.1 ± 32.5 compared to
199 53.8 ± 35.7 in the control group ($p=0.023$). The between group AUC_{1-12} differences for

200 individual Jackson symptoms were consistently lower in the treatment group compared to the
201 control group. The most prominent differences were seen in sore throat and blocked nose as
202 shown in Figure 2 expressed as differences in AUC_{1-12} (95% CI). The mean daily sum score
203 of morning and evening values are shown in Figure 3a, and scores of individual Jackson items
204 over 12 days are shown in Appendix A.

205

206 One subject in the treatment group did not answer the 9-item WURSS-21 QoL domain
207 questionnaire. Another 14 subjects (eight in the treatment group) misinterpreted the
208 questionnaire by reporting a severe impact on quality of life at the end of the cold in spite of
209 being fully recovered. Data from these subjects were considered invalid resulting in a FAS
210 analysis of the 9-item WURSS-21 QoL domain of 127 and 125 subjects in the treatment and
211 control group, respectively. The impact on quality of life integrated over 12 days was
212 significantly lower in the treatment group with an AUC_{1-12} of 113.6 ± 107.7 compared to
213 152.7 ± 126.3 in the control group ($p=0.006$). The between group AUC_{1-12} differences were
214 significantly lower for all individual items of the WURSS-21 QoL domain (Figure 2) in
215 favour of treatment. The mean daily sum score of 9-item WURSS-21 QoL domain also
216 showed a significant difference in favour of treatment on day two and thereafter (Figure 3b).

217

218 All nine individual QoL domain items were consistently lower with treatment compared to
219 without treatment during the first week, with a significant difference seen within the first 12
220 hours for item 15 (walk, climb stairs, exercise) and item 19 (interact with others), as shown in
221 Appendix B.

222

223 The duration of the common cold defined as the number of days from symptom start until the
224 last day before answering “No” to the question “Do you think that you still have a common

225 cold” for two days in a row was 6.26 ± 3.27 in the treatment group and 7.10 ± 4.06 in the
226 control group ($p=0.125$). When defined as number of days with a total Jackson score > 0 ,
227 colds duration in the treatment group was 7.11 ± 3.37 and in the control group 8.08 ± 4.13
228 ($p=0.071$). Corresponding data for the 9-item WURSS-21 QoL domain was 6.46 ± 3.48 and
229 7.62 ± 4.18 days respectively ($p=0.030$). The number of subjects scoring zero for individual
230 Jackson symptoms day by day during the course of the common cold is shown in Table 2 and
231 for the respective 9 items of WURSS-21 QoL domain in Table 3.

232

233 Concomitant medication was used less often (2.3 ± 3.0 days) by the treatment group than the
234 control group (3.2 ± 3.2 days, $p=0.032$) over the first 7 days of a cold and over 14 days ($5.0 \pm$
235 6.4 versus 6.7 ± 6.7 , $p=0.032$). During the first week a significant difference in the number of
236 subjects using symptom relieving medications was seen on day one, three and four, as shown
237 in Figure 4.

238

239 Of the 136 participants in the treatment group 115 evaluated the efficacy at the end of the
240 study. The assessment “very good” or “good” was admitted by 95 subjects (82.6%). Product
241 tolerability and safety was evaluated by 116 subjects and was considered to be “very good” or
242 “good” by 115 (99.1%) and 114 (98.3%), respectively. A total of 14 subjects (14 of 400;
243 3.5%) suffered from adverse events, four in the treatment group compared to ten in the control
244 group. No adverse event was considered by the investigators to be related to treatment. One
245 serious adverse event, appendicitis, occurred in the treatment group.

246

247 **CONCLUSION**

248 This single-blinded, randomised controlled trial was conducted to assess whether this study
249 design can adequately evaluate the common cold using symptom scoring with the Jackson

250 scale as well as by quality of life scoring with the 9-item WURSS-21 QoL domain. A
251 secondary objective was to investigate whether treatment with a glycerol throat spray
252 containing cold-adapted cod trypsin (GCTS) when initiated at the first self-perceived
253 prodromal symptoms can alleviate and shorten a common cold. The 9-item WURSS-21 QoL
254 domain composite score, as well as eight out of nine individual QoL items, seem to be a most
255 sensitive instrument for demonstrating that GCTS treatment compared to no treatment
256 significantly improves the colds sufferers' quality of life over 12 days (AUC_{1-12}). The
257 reduction in Jackson AUC_{1-12} was likewise significantly reduced with active treatment
258 although less discriminating than the 9-item WURSS-21 QoL domain. These results, together
259 with significantly less use of rescue medication, and an approximately one day quicker
260 recovery are all indicative of a positive effect after treatment with a glycerol-cod trypsin
261 throat spray (GCTS).

262

263 The outcome of this study supports previous findings of a randomised placebo-controlled
264 pilot study on healthy volunteers treated with the same glycerol-cod trypsin throat spray in
265 which a lower oropharyngeal virus load and a reduced duration of common cold symptoms
266 was shown following experimental intranasal inoculation of rhinovirus-16 [12]. Further, two
267 open-label studies using participants as their own historical controls showed reduced sick
268 leave time in kindergarten employees [17] and elderly care personnel [18] when treated with
269 the glycerol-cod trypsin spray during the common cold season.

270

271 Interestingly, the 9 item WURSS-21 QoL domain was more informative than the total
272 Jackson symptom severity scores in discerning the effect of treatment particularly on days 1
273 and 2. The 9 item WURSS-21 QoL domain found significant differences benefiting the
274 treated group beginning one day earlier (day 2 vs. day 3) compared to the Jackson scale. It

275 might be argued that this early difference in quality of life is the result of inclusion skewness
276 nonetheless randomisation and an almost identical Jackson score from the start favour an
277 early alleviating effect of treatment best detected by the WURSS-21 QoL domain.

278

279 Many, if not most, prior experimental protocol designs have relied on the Jackson scale [13]
280 for self-diagnosis at entry and to describe the evolution of symptoms despite the fact that it is
281 not validated and often modified. Nonetheless, most studies evaluating treatments for the
282 common cold have employed Jackson criteria as a primary outcome measure [4, 19] or for
283 validating new questionnaires [14, 20], or assessing the relationship between common cold
284 symptoms and biological parameters [21]. On the contrary, the WURSS-21 questionnaire [14]
285 is an illness-specific health-related quality of life instrument that has been validated against
286 the Jackson scale and the SF-8 Health Survey, demonstrating a high correlation. The 9-item
287 quality of life domain of WURSS-21 has not been validated separately but does show a
288 correlation with Jackson score in the present study (see Appendix C). Although the
289 correlation is not perfect, a Bland-Altman analysis shows that the limits of agreement, a
290 measure of both bias and random variation, correspond to two to three times what is generally
291 considered a minimal clinically important difference of WURSS-21, i.e. 1 unit of 7.
292 Furthermore, the differences between the two scores seem to be mainly random, reflecting the
293 scores reliability rather than bias.

294

295 Investigations into the sources of bias in the design of randomised clinical trials have found
296 that binary variables are generally less subject to bias than continuous variables [22]. In this
297 design all subjects made a binary decision as to when they became ill with a common cold
298 (the start) and made subsequent daily binary decisions supporting how long they were ill.
299 Thus, while these decisions must integrate internal signals of the state of their illness, they are

300 nevertheless binary determinants of illness presence and duration. Using these measures, the
301 treatment group demonstrated a significant difference from the no treatment group in illness
302 duration using the QoL instrument ($p=0.03$) and near significance using the Jackson scale to
303 determine number of days greater than zero ($p=0.07$). These results accord with overall
304 efficacy outcomes derived from subjective symptom and QoL scales including overall
305 symptom burdens (AUCs).

306

307 According to Krogsbøll et al [23], in designs with a treatment, placebo and no treatment arms
308 there are three sources of positive effect: placebo, treatment and spontaneous improvement.
309 The latter describes all acute self-limiting conditions including the common cold. In this
310 design the latter would be accelerated by palliative treatment. The no treatment group acts as
311 a control for spontaneous improvement. The placebo effect is generally driven by both
312 expectation and conditioning [24]. In these two respects consumers would not expect oral
313 sprays to be effective as treatments for a nasal disorder, but rather nasal saline, nasal
314 decongestants, or colds tablets. Lastly, in normal subjects without preconditioning, no placebo
315 effect (lactose tablet) was found over no treatment for subjective expectancy, or their outcome
316 measures, using a battery of 5 psychological tests sensitive to biases in emotional processing
317 that occur prior to subjective change [25].

318

319 There are possible limitations to this study. First, participants were asked to self-diagnose the
320 onset of an emerging common cold while simultaneously experiencing a total Jackson score
321 of at least one for any symptom (except headache). Higher Jackson scores are normally
322 required to accept inclusion in symptomatic relief trials [19, 26]. But to reduce early virus
323 propagation and replication it was judged essential that the tested throat spray is applied as
324 early as possible. Since no objective signs of a common cold are present during prodrome, we

325 instead hypothesized that years of personal experience catching colds makes each subject the
326 best predictor of their imminent illness. Such methods are similar to those of other natural
327 colds studies [8, 14 and 26].

328

329 Second, while the primary objective of this methods trial was to assess the suitability of
330 different rating instruments to detect illness burden and treatment effects this study was
331 secondarily designed to provide a proof of concept of the tested product. Despite the fact that
332 multiple endpoints were studied it is unlikely that these positive results were caused by
333 chance due to multiplicity since pre-defined hypotheses were tested and the multiple
334 endpoints were not independent but related. The consistent results in favour of active
335 treatment point towards a true effect of the tested product on colds illness.

336

337 Third, since this trial was designed to compare active treatment with a medical device to no
338 treatment it is possible that the observed outcomes were due to a placebo effect. The no
339 treatment group should adequately control for a self-limiting condition or spontaneous
340 improvement [27] in a randomised clinical trial with patient-reported outcomes [28]. More
341 recently a study looking at the placebo effect of oral *Echinacea* for treatment of the common
342 cold, using *a priori* analyses of cold duration and the AUC for the WURSS-21, determined
343 that the placebo effect was limited [29].

344

345 The results presented here indicate that a quality of life instrument (9-item WURSS-21 QoL
346 domain) can detect colds illness and the effect of treatment with a throat spray designed as an
347 active physical barrier to viral entry into mucosal cells in the oro-pharynx [7, 9-11].

348 In summary, the results of this methods trial remind us that consumers integrate the effects of
349 emerging symptom complexes and quickly recognize the signals of a common cold illness

350 and their emerging reduced functionality. Given heightened global awareness of other
351 circulating respiratory viruses of greater morbidity, such as SARS-CoV-2 and influenza,
352 quality of life domains should be considered in determining wellness and recovery from these
353 infections.

354

355 **References**

356 ¹ Fendrick AM, Monto AS, Nightengale B, Sarnes M. The economic burden of non-influenza-
357 related viral respiratory tract infection in the United States. *Arch Intern Med* 2003; **163**: 487–
358 494.

359 ² Bramley J, Lerner D, Sarnes M. Productivity Losses Related to the Common Cold. *J Occup*
360 *Environ Med* 2002; **44**: 822–829.

361 ³ Heikkinen T, Järvinen A. The Common Cold, *Lancet* 2003; **361**: 51–59.

362 ⁴ Turner R, Bauer R, Woelkart K, Hulseley TC, Gangemi JD. An Evaluation of *Echinacea*
363 *angustifolia* in Experimental Rhinovirus Infections. *N Engl J Med* 2005; **353**: 341-48.

364 ⁵ Hemilä H, Chalker E. Vitamin C for preventing and treating the common cold. *Cochrane*
365 *Database of Systematic Reviews* 2013; **Issue 1**.

366 ⁶ Lissiman E, Bhasale AL, Cohen M. Garlic for the common cold. *Cochrane Database of*
367 *Systematic Reviews* 2014; **Issue 11**.

368 ⁷ Winther B, Gwaltney JM Jr, Mygind N, Turner RB, Hendley JO. Sites of Rhinovirus
369 Recovery After Point Inoculation of the Upper Airway. *JAMA* 1986; **256**: 1763-1767.

370 ⁸ Witek TJ, Ramsey DL, Carr AN, Riker DK. The Natural History of community-acquired
371 common colds symptoms assessed over 4-years. *Rhinology* 2015; **53**: 81–88.

372 ⁹ Gudmundsdóttir A, Hilmarsson H, Stefansson B. Potential use of Atlantic cod trypsin in
373 Biomedicine. *Biomed Res Int* 2013; **2013**: 749078

- 374 ¹⁰ Stefansson B, Gudmundsdottir A, Clarsund M. A medical device forming a protective
375 barrier that deactivates four major common cold viruses. *Viol Res Rev* 2017; **1**: 1–3.
- 376 ¹¹ Stefansson B, Scheving R, Nelson I, Sigurgeirsson B. ColdZyme forms a protective barrier
377 in the oropharynx that deactivates major common cold viruses. Abstract presented at 3rd
378 European Otolaryngology-ENT Surgery Conference, London, UK 2018; October 08-10.
- 379 ¹² Clarsund M, Fornbacke M, Uller L, Johnston S, Emanuelsson C. A Randomized, Double-
380 Blind, Placebo-Controlled Pilot Clinical Study on ColdZyme® Mouth Spray against
381 Rhinovirus-Induced Common Cold. *Open Journal of Respiratory Diseases* 2017; **7**: 125–135.
- 382 ¹³ Jackson GG, Dowling HF, Spiesman, IG, Board, AV. Transmission of the common cold to
383 volunteers under controlled conditions. I. The common cold as a clinical entity. *AMA Arch*
384 *Intern Med.* 1958; **101**): 267–78.
- 385 ¹⁴ Barrett B, Brown RL, Mundt MP, Thomas GR, Barlow SK, Highstrom AD, Bahrainian M.
386 Validation of a short form Wisconsin Upper Respiratory Symptom Survey (WURSS-21).
387 *Health Qual Life Outcomes* 2009; **12**: 7–76.
- 388 ¹⁵ Auinger A, Riede L, Bothe G, Busch R, Gruenwald J. Yeast (1,3) - (1,6)-beta-glucan helps
389 to maintain the body's defence against pathogens: a double-blind, randomized, placebo-
390 controlled, multicentric study in healthy subjects. *Eur J Nutr* 2013; **52**: 1913–1918.
- 391 ¹⁶ Riede L, Grube B, Gruenwald J. Larch arabinogalactan effects on reducing incidence of
392 upper respiratory infections. *Curr Med Res Opin* 2013; **29**: 251-258.
- 393 ¹⁷ Clarsund M. Evaluation of ColdZyme Mouth Spray against Common Cold in Preschool
394 Staff. *Open Journal of Respiratory Diseases* 2017; **7**: 136–140.
- 395 ¹⁸ Clarsund M, Bråkenhielm Persson C. Evaluation of ColdZyme Mouth Spray against
396 Common Cold in Elderly Care Personnel. *Open Journal of Respiratory Diseases* 2016; **7**: 12–
397 17.

- 398 ¹⁹ Eccles R, Winther B, Johnston SL, Robinson P, Trampisch M, Koelsch S. Efficacy and
399 safety of iota-carrageenan nasal spray versus placebo in early treatment of the common cold
400 in adults: the ICICC trial. *Respiratory Research* 2015; **16**: 121.
- 401 ²⁰ Barrett B, Brown R, Mundt M, et al. The Wisconsin upper respiratory symptom survey is
402 responsive, reliable, and valid. *J Clin Epidemiol* 2005; **58**: 609–617.
- 403 ²¹ Barrett B, Brown R, Voland R, Maberry R, Turner R. Relations among questionnaire and
404 laboratory measures of rhinovirus infection. *Eur Resp J* 2006; **28**: 358-363
- 405 ²² Hrobjartsson, Gøtzsche. Is the Placebo Powerless? An Analysis of Clinical Trials
406 Comparing Placebo with No Treatment. *New Engl J Med* 2001; **344**: 1594-1602.
- 407 ²³ Krogsboll, Hrobjartsson, Gøtzsche. Spontaneous Improvement in Randomized Clinical
408 Trials: Meta-analysis of Three-armed Trials Comparing No Treatment, Placebo and Active
409 Intervention. *BMC Med Research Methodology* 2009; **9**: 1-10.
- 410 ²⁴ Stewart-Williams, Podd. The Placebo Effect: Dissolving the Expectancy Versus
411 Conditioning Debate. *Psychological Bulletin* 2004; **130(2)**: 324 –340.
- 412 ²⁵ Huneke, Walsh, Brown, Browning, Harmer. No evidence for an acute placebo effect on
413 emotional processing in healthy volunteers. *J Psychopharmacol.* 2017; **Dec;31(12)**: 1578-
414 1587.
- 415 ²⁶ Yale SH, Liu k. Echinacea purpurea Therapy for the Treatment of the Common Cold. *Arch*
416 *Intern Med* 2004; **164**: 1237-1241.
- 417 ²⁷ Kienle GS, Kiene H. The Powerful Placebo Effect: Fact or Fiction? *J Clin Epidemiol* 1997;
418 **50**: 1311–1318.
- 419 ²⁸ Hróbjartsson A, Gøtzsche PC. Placebo interventions for all clinical conditions. *The*
420 *Cochrane Library* 2010, Issue 1.
- 421 ²⁹ Barrett B, Brown R, Rakel D et al. Placebo Effects and the Common Cold: A Randomized
422 Controlled Trial. *Ann Fam Med* 2011; **9**: 312-322.

423 **Conflict of Interests**

424 F.L. was employed by Enzymatica AB when the study was conducted and is currently a
425 member of the Board of Enzymatica. Current affiliation for F.L. is AGB-Pharma AB, 222 20
426 Lund, Sweden. F.L. has a patent pending. I.N is employed by Enzymatica AB. J.R. and D.R.
427 have provided consultancy services and have received payment from Enzymatica AB for
428 services rendered. The authors have submitted the ICMJE Form for Disclosure of Potential
429 Conflicts of Interest.

430 **Funding**

431 This work was supported by Enzymatica AB.

432 **Data Availability Statement**

433 Individual participant data, after having been anonymized will be made available, along with
434 the study protocol, statistical analysis plan and consent form. Data will be made available
435 beginning 3 months and ending 5 years after publication of the article to researchers whose
436 proposed use of the data is approved by the original study investigators. Proposals should be
437 directed to the corresponding author and requesters will need to sign a data access agreement.

438 **Tables and figures; Legends**

439 Table 1: Baseline characteristics of the full analysis set (FAS) population

440 Table 2: Number of subjects (% of subjects in respective group) without symptoms for each
441 individual item of the Jackson score during the first 8 days of the common cold (mean of
442 morning and evening ratings).

443 Table 3: Number of subjects (% of subjects in respective group) without symptoms for each
444 individual item of the 9-item WURSS-21 QoL domain during the first 8 days of the common
445 cold (evening ratings).

446

447 Figure 1: Trial profile

448 Figure 2: Forest plot analyses of individual items of 9-item WURSS-21 QoL domain and 8-
449 item Jackson symptom ratings

450 Figure 3: Mean daily sum score over 12 days based on morning and evening values for
451 Jackson score and evening values for the 9-item WURSS-21 QoL domain

452 Figure 4: Daily frequency of subjects using rescue medication

453

454 **Appendices**

455 Appendix A: Jackson score individual items morning and evening day 1-12

456 Appendix B: 9-item WURSS-21 QoL domain individual items: Daily mean score day 1-12

457 Appendix C: Comparison between Jackson score and 9-item WURSS-21 QoL domain



CONSORT 2010 Flow Diagram




Figure 1: Trial profile





Figure 2: Forest plot analyses of individual items of 9-item WURSS-21 QoL domain and 8-item Jackson symptom ratings; significant differences shown in bold ($p < 0.05$) WURSS=Wisconsin Upper Respiratory Symptom Survey, QoL=quality of life

A. Total Jackson score



B. 9-item WURSS-21 QoL domain score




Figure 3: Mean daily sum score over 12 days based on morning and evening values for Jackson score and evening values for the 9-item WURSS-21 QoL domain.

WURSS=Wisconsin Upper Respiratory Symptom Survey, QoL=quality of life.




Figure 4: Daily frequency of subjects using rescue medication

* p < 0.05

Table 1: Baseline characteristics of the full analysis set (FAS) population.

| | Treatment group (n=136) | Control group (n=131) |
|----------------------------------|------------------------------------|----------------------------------|
| Age (years) | 42.7 (13.8) | 38.3 (13.2) |
| Sex (female) | 92 (67.6 %) | 98 (74.8 %) |
| Caucasian | 132 (97.1 %) | 127 (96.9 %) |
| Systolic blood pressure (mm Hg) | 126.6 (13.8) | 124.8 (12.1) |
| Diastolic blood pressure (mm Hg) | 78.2 (7.9) | 77.0 (7.6) |
| Pulse rate (bpm) | 73.2 (7.9) | 72.0 (8.6) |

Data are mean (SD); n (%).

Table 2: Number of subjects (% of subjects in respective group) without symptoms for each individual item of the Jackson score during the first 8 days of the common cold (mean of morning and evening ratings); bold values indicate significance below p=0.05.

| Sore throat | Treatment (n=136) | Control (n=131) | p-value | Blocked nose | Treatment (n=136) | Control (n=131) | p-value | Runny nose | Treatment (n=136) | Control (n=131) | p-value |
|--------------------|-------------------|-----------------|--------------|---------------------|-------------------|-----------------|--------------|-------------------|-------------------|-----------------|--------------|
| Day 1 | 20 (14.7) | 19 (14.5) | 1.000 | Day 1 | 38 (27.9) | 40 (30.5) | 0.687 | Day 1 | 42 (30.9) | 41 (31.3) | 1.000 |
| Day 2 | 12 (8.8) | 18 (13.7) | 0.246 | Day 2 | 34 (25.0) | 30 (22.9) | 0.775 | Day 2 | 33 (24.3) | 32 (24.4) | 1.000 |
| Day 3 | 21 (15.4) | 21 (16.0) | 1.000 | Day 3 | 43 (31.6) | 25 (19.1) | 0.024 | Day 3 | 38 (27.9) | 32 (24.4) | 0.578 |
| Day 4 | 38 (27.9) | 33 (25.2) | 0.678 | Day 4 | 53 (39.0) | 36 (27.5) | 0.052 | Day 4 | 51 (37.5) | 39 (29.8) | 0.197 |
| Day 5 | 68 (50.0) | 46 (35.1) | 0.019 | Day 5 | 67 (49.3) | 53 (40.5) | 0.176 | Day 5 | 65 (47.8) | 54 (41.2) | 0.325 |
| Day 6 | 79 (58.1) | 67 (51.1) | 0.270 | Day 6 | 82 (60.3) | 72 (55.0) | 0.389 | Day 6 | 81 (59.6) | 69 (52.7) | 0.269 |
| Day 7 | 96 (70.6) | 82 (62.6) | 0.194 | Day 7 | 93 (68.4) | 83 (63.4) | 0.439 | Day 7 | 88 (64.7) | 82 (62.6) | 0.799 |
| Day 8 | 110 (80.9) | 98 (74.8) | 0.242 | Day 8 | 104 (76.5) | 94 (71.8) | 0.575 | Day 8 | 103 (75.7) | 95 (72.5) | 0.578 |
| Cough | Treatment (n=136) | Control (n=131) | p-value | Sneezing | Treatment (n=136) | Control (n=131) | p-value | Headache | Treatment (n=136) | Control (n=131) | p-value |
| Day 1 | 46 (33.8) | 55 (42.0) | 0.207 | Day 1 | 31 (22.8) | 44 (33.6) | 0.057 | Day 1 | 47 (34.6) | 37 (28.2) | 0.293 |
| Day 2 | 29 (21.3) | 41 (31.3) | 0.071 | Day 2 | 36 (26.5) | 35 (26.7) | 1.000 | Day 2 | 45 (33.1) | 34 (26.0) | 0.228 |
| Day 3 | 33 (24.3) | 33 (25.2) | 0.888 | Day 3 | 42 (30.9) | 36 (27.5) | 0.591 | Day 3 | 47 (34.6) | 32 (24.4) | 0.082 |
| Day 4 | 56 (41.2) | 38 (29.0) | 0.041 | Day 4 | 65 (47.8) | 52 (39.7) | 0.217 | Day 4 | 67 (49.3) | 51 (38.9) | 0.109 |
| Day 5 | 74 (54.4) | 51 (38.9) | 0.014 | Day 5 | 90 (66.2) | 67 (51.1) | 0.013 | Day 5 | 92 (67.6) | 62 (47.3) | 0.001 |
| Day 6 | 86 (63.2) | 59 (45.0) | 0.003 | Day 6 | 104 (76.5) | 81 (61.8) | 0.012 | Day 6 | 104 (76.5) | 83 (63.4) | 0.023 |
| Day 7 | 93 (68.4) | 74 (56.5) | 0.076 | Day 7 | 107 (78.7) | 98 (74.8) | 0.472 | Day 7 | 116 (85.3) | 101 (77.1) | 0.116 |
| Day 8 | 102 (75.0) | 93 (71.0) | 0.492 | Day 8 | 116 (85.3) | 113 (86.3) | 0.862 | Day 8 | 120 (88.2) | 110 (84.0) | 0.377 |
| Malaise | Treatment (n=136) | Control (n=131) | p-value | Chilliness | Treatment (n=136) | Control (n=131) | p-value | | | | |
| Day 1 | 48 (35.3) | 45 (34.4) | 0.898 | Day 1 | 72 (52.9) | 70 (53.4) | 1.000 | | | | |

| | | | | | | | | | | | | | |
|-------|------------|------------|--------------|-------|------------|------------|-------|--|--|--|--|--|--|
| Day 2 | 40 (29.4) | 37 (28.2) | 0.893 | Day 2 | 72 (52.9) | 71 (54.2) | 0.902 | | | | | | |
| Day 3 | 47 (34.6) | 41 (31.3) | 0.604 | Day 3 | 86 (63.2) | 78 (59.5) | 0.615 | | | | | | |
| Day 4 | 65 (47.8) | 58 (44.3) | 0.624 | Day 4 | 108 (79.4) | 95 (72.5) | 0.200 | | | | | | |
| Day 5 | 84 (61.8) | 65 (49.6) | 0.049 | Day 5 | 114 (83.8) | 102 (77.9) | 0.276 | | | | | | |
| Day 6 | 101 (74.3) | 86 (65.6) | 0.142 | Day 6 | 126 (92.6) | 116 (88.5) | 0.296 | | | | | | |
| Day 7 | 111 (81.6) | 99 (75.6) | 0.236 | Day 7 | 127 (93.4) | 120 (91.6) | 0.646 | | | | | | |
| Day 8 | 121 (89.0) | 108 (82.4) | 0.161 | Day 8 | 128 (94.1) | 124 (94.7) | 1.000 | | | | | | |

Table 3: Number of subjects (% of subjects in respective group) without symptoms for each individual item of the 9-item WURSS-21 QoL domain during the first 8 days of the common cold (evening ratings); bold values indicate significance below p=0.05.

| Item 12 Think clearly | | | | Item 13 Sleep well | | | | Item 14 Breathe easily | | | |
|--------------------------------------|-------------------|-----------------|------------------|-------------------------------------|-------------------|-----------------|------------------|---------------------------------|-------------------|-----------------|------------------|
| Item 12 | Treatment (n=127) | Control (n=125) | p-value | Item 13 | Treatment (n=127) | Control (n=125) | p-value | Item 14 | Treatment (n=127) | Control (n=125) | p-value |
| Day 1 | 63 (49.6) | 54 (43.2) | 0.316 | Day 1 | 29 (22.8) | 24 (19.2) | 0.538 | Day 1 | 20 (15.7) | 22 (17.6) | 0.737 |
| Day 2 | 51 (40.2) | 34 (27.2) | 0.033 | Day 2 | 21 (16.5) | 12 (9.6) | 0.135 | Day 2 | 18 (14.2) | 15 (12.0) | 0.710 |
| Day 3 | 58 (45.7) | 37 (29.6) | 0.009 | Day 3 | 28 (22.0) | 21 (16.8) | 0.341 | Day 3 | 26 (20.5) | 18 (14.4) | 0.246 |
| Day 4 | 68 (53.5) | 44 (35.2) | 0.002 | Day 4 | 40 (31.5) | 27 (21.6) | 0.088 | Day 4 | 42 (33.1) | 28 (22.4) | 0.068 |
| Day 5 | 83 (65.4) | 52 (41.6) | <0.001 | Day 5 | 57 (44.9) | 38 (30.4) | 0.020 | Day 5 | 55 (43.3) | 39 (31.2) | 0.052 |
| Day 6 | 90 (70.9) | 65 (52.0) | 0.003 | Day 6 | 69 (54.3) | 47 (37.6) | 0.008 | Day 6 | 61 (48.0) | 47 (37.6) | 0.100 |
| Day 7 | 98 (77.2) | 84 (67.2) | 0.092 | Day 7 | 83 (65.4) | 61 (48.8) | 0.011 | Day 7 | 80 (63.0) | 59 (47.2) | 0.016 |
| Day 8 | 106 (83.5) | 92 (73.6) | 0.066 | Day 8 | 95 (74.8) | 78 (62.4) | 0.042 | Day 8 | 89 (70.1) | 78 (62.4) | 0.231 |
| Item 15 Walk, climb stairs, exercise | | | | Item 16 Accomplish daily activities | | | | Item 17 Work outside the home | | | |
| Item 15 | Treatment (n=127) | Control (n=125) | p-value | Item 16 | Treatment (n=127) | Control (n=125) | p-value | Item 17 | Treatment (n=127) | Control (n=125) | p-value |
| Day 1 | 48 (37.8) | 36 (28.8) | 0.143 | Day 1 | 46 (36.2) | 36 (28.8) | 0.228 | Day 1 | 50 (39.4) | 39 (31.2) | 0.189 |
| Day 2 | 37 (29.1) | 26 (20.8) | 0.146 | Day 2 | 33 (26.0) | 26 (20.8) | 0.373 | Day 2 | 41 (32.3) | 24 (19.2) | 0.021 |
| Day 3 | 44 (34.6) | 29 (23.2) | 0.052 | Day 3 | 43 (33.9) | 29 (23.2) | 0.070 | Day 3 | 47 (37.0) | 34 (27.2) | 0.107 |
| Day 4 | 59 (46.5) | 31 (24.8) | <0.001 | Day 4 | 63 (49.6) | 36 (28.8) | 0.001 | Day 4 | 61 (48.0) | 38 (30.4) | 0.005 |
| Day 5 | 70 (55.1) | 43 (34.4) | 0.001 | Day 5 | 77 (60.6) | 50 (40.0) | 0.002 | Day 5 | 77 (60.6) | 49 (39.2) | 0.001 |
| Day 6 | 84 (66.1) | 55 (44.4) | 0.001 | Day 6 | 89 (70.1) | 58 (46.4) | <0.001 | Day 6 | 91 (71.7) | 60 (48.0) | <0.001 |
| Day 7 | 95 (74.8) | 73 (58.4) | 0.007 | Day 7 | 97 (76.4) | 78 (62.4) | 0.020 | Day 7 | 97 (76.4) | 76 (60.8) | 0.010 |
| Day 8 | 104 (81.9) | 89 (71.2) | 0.053 | Day 8 | 106 (83.5) | 93 (74.4) | 0.090 | Day 8 | 107 (84.3) | 91 (72.8) | 0.032 |
| Item 18 Work inside the home | | | | Item 19 Interact with others | | | | Item 20 Live your personal life | | | |
| Item 18 | Treatment (n=127) | Control (n=125) | p-value | Item 19 | Treatment (n=127) | Control (n=125) | p-value | Item 20 | Treatment (n=127) | Control (n=125) | p-value |

| | | | | | | | | | | | |
|-------|------------|-----------|------------------|-------|------------|-----------|--------------|-------|------------|-----------|--------------|
| Day 1 | 51 (40.2) | 40 (32.0) | 0.192 | Day 1 | 49 (38.6) | 42 (33.6) | 0.433 | Day 1 | 48 (37.8) | 43 (34.4) | 0.602 |
| Day 2 | 40 (31.5) | 28 (22.4) | 0.119 | Day 2 | 51 (40.2) | 34 (27.2) | 0.033 | Day 2 | 43 (33.9) | 33 (26.4) | 0.218 |
| Day 3 | 46 (36.2) | 34 (27.2) | 0.138 | Day 3 | 51 (40.2) | 35 (28.0) | 0.047 | Day 3 | 53 (41.7) | 35 (28.0) | 0.025 |
| Day 4 | 66 (52.0) | 41 (32.8) | 0.002 | Day 4 | 67 (52.8) | 41 (32.8) | 0.002 | Day 4 | 68 (53.6) | 42 (33.6) | 0.002 |
| Day 5 | 82 (64.6) | 55 (44.0) | 0.002 | Day 5 | 77 (60.6) | 55 (44.0) | 0.011 | Day 5 | 83 (65.4) | 56 (44.8) | 0.001 |
| Day 6 | 91 (71.7) | 62 (49.6) | <0.001 | Day 6 | 90 (70.9) | 65 (52.0) | 0.003 | Day 6 | 92 (72.4) | 71 (56.8) | 0.012 |
| Day 7 | 99 (78.0) | 80 (64.0) | 0.018 | Day 7 | 95 (74.8) | 83 (66.4) | 0.167 | Day 7 | 98 (77.2) | 88 (70.4) | 0.253 |
| Day 8 | 109 (85.8) | 95 (76.0) | 0.055 | Day 8 | 106 (83.5) | 95 (76.0) | 0.160 | Day 8 | 108 (85.0) | 98 (78.4) | 0.194 |

WURSS=Wisconsin Upper Respiratory Symptom Survey, QoL= Quality of Life